Merck KGaA Acquires Bio-Techne Corporation (NASDAQ:TECH): Market Reaction and Shareholder Value

• Merck KGaA is set to acquire Bio-Techne Corporation (NASDAQ:TECH) in an all-cash transaction at $73.00 per share.
• The acquisition price represents a 24% premium, leading to a 19.80% surge in Bio-Techne Corporation shares.
• An investor rights law firm is investigating the deal to ensure the $73.00 per share offer is fair for Bio-Techne Corporation shareholders.

Bio-Techne Corporation (NASDAQ:TECH) is a U.S. company that supplies tools and other products for laboratory and clinical research. The company is now the subject of a major acquisition. Germany's Merck KGaA agrees to purchase Bio-Techne Corporation in an all-cash transaction, a move designed to strengthen its life sciences business.

In light of the acquisition, Leerink Partners changes its rating for Bio-Techne Corporation to Market Perform from Outperform. The investment firm sets a new price target for the stock at $73.00. This target directly matches the acquisition price offered by Merck KGaA for each share of the company.

The $73.00 per share cash offer gives Bio-Techne Corporation an enterprise value of approximately US$11.3 billion. This price represents a significant premium for shareholders. As highlighted by The Wall Street Journal, the offer is a 24% premium over the stock's closing price on the previous Wednesday.

The market reacts to the deal, with shares of Bio-Techne Corporation surging by 19.80% to a price of $70.54. This price is just below the acquisition price, leaving a potential upside of about 3.48% to the $73.00 target. The stock's trading volume is high, with around 38.38 million shares changing hands.

Despite the premium, the investor rights law firm Halper Sadeh LLC launches an investigation into the sale. The firm questions if the $73.00 per share price is fair. The investigation assesses whether Bio-Techne's board is securing the best possible price for its shareholders.